Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
PerkinElmer (NYSE: PKI) announced the pricing of a total of $2.3 billion in senior notes, with maturities ranging from 2023 to 2031. This includes $500 million of 0.550% notes due 2023, $800 million of 0.850% notes due 2024, $500 million of 1.900% notes due 2028, and $500 million of 2.250% notes due 2031. The proceeds are intended to partially finance the acquisition of BioLegend, Inc. The offering is set to close on September 10, 2021.
PerkinElmer, Inc. (NYSE: PKI) will present at the Baird Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. During the virtual event, Steve Willoughby, Vice President of Investor Relations, will discuss the company's strategic priorities. A live audio webcast can be accessed in the Investors section of the company's website, with a replay available for 90 days post-event. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and has over 14,000 employees worldwide.
PerkinElmer reported robust financial results for Q2 2021, with GAAP EPS of $2.19, up from $1.23 in Q2 2020. Revenue surged to $1.228 billion from $812 million, reflecting a growth rate of 51%. Operating income also rose significantly to $332 million, yielding an operating profit margin of 27.1%. The company announced an acquisition of BioLegend for $5.25 billion and raised its full-year guidance to $4.57 billion in revenue and $9.88 in EPS. The acquisition is expected to enhance its market position.
PerkinElmer (NYSE: PKI) has announced an agreement to acquire BioLegend for approximately $5.25 billion in cash and stock, marking the largest transaction in PerkinElmer’s history. This strategic acquisition aims to enhance PerkinElmer’s life science offerings, particularly in high-growth areas like proteogenomics and cell separation. BioLegend is expected to generate around $380 million in revenue for 2022 and will transition into PerkinElmer’s Center of Excellence for research reagents. The deal anticipates earnings accretion of $0.30 per share in the first year.
PerkinElmer, Inc. (NYSE: PKI) announced a quarterly dividend of $0.07 per share on July 23, 2021. The dividend is scheduled for payment on November 12, 2021, to shareholders of record as of October 22, 2021. PerkinElmer reported a revenue of approximately $3.8 billion in 2020 and employs around 14,000 people across 190 countries. The company is also included in the S&P 500 Index.
PerkinElmer (NYSE: PKI) announced it expects to exceed its financial guidance for Q2 ending July 4, 2021, driven by strong performance in both COVID and non-COVID sectors. A Virtual Investor and Analyst Day is set for today, featuring presentations from key executives. The company will release its Q2 financial results after market close on July 28, followed by a conference call at 5:00 p.m. ET the same day. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people globally.
PerkinElmer (NYSE: PKI) has announced its agreement to acquire SIRION Biotech GmbH, a leader in viral vector-based technologies essential for cell and gene therapies. The transaction is expected to conclude in Q3 2021. With SIRION's innovative offerings, PerkinElmer aims to enhance its Horizon Discovery portfolio, which already includes advanced gene editing tools. This acquisition aligns with the growing demand for viral vector approaches in gene therapy, particularly in treating diseases like cancer.
Oxford Immunotec, part of PerkinElmer, announced its T-SPOT® Discovery SARS-CoV-2 kit is utilized in the UK COVID-19 Human Challenge Study. This national collaboration aims to expedite vaccine development against COVID-19 by identifying effective viral doses in a controlled setting. The study began in March 2021, focusing on analyzing immune responses, particularly T cell reactions. The T-SPOT technology is employed to enhance understanding of immune responses, thus aiding future vaccine efficacy studies. The kit is currently for research use only.
PerkinElmer (NYSE: PKI) has agreed to acquire Immunodiagnostic Systems Holdings PLC (LSE: IHS) for about $155 million (£110 million), enhancing its diagnostics capabilities, particularly in immunodiagnostics. The deal, with an enterprise value of approximately $124 million (£88 million), is expected to close by early Q3 2021, pending shareholder and court approvals. This acquisition will integrate IDS's chemiluminescence products with PerkinElmer's offerings, creating synergies and expanding their global presence in key diagnostic markets.
PerkinElmer, Inc. (NYSE: PKI) has announced its agreement to acquire Nexcelom Bioscience for $260 million in cash, expected to close in Q2 2021. Nexcelom specializes in automated cell counting instruments and cytometry, generating approximately $40 million in 2021 revenues. This acquisition aims to enhance PerkinElmer's drug discovery solutions and streamline workflows for clients in academia and biopharmaceuticals. The deal follows PerkinElmer's recent acquisition of Horizon Discovery, indicating a strong push towards expanding capabilities in life sciences.